Complication Rate of Transfemoral Endomyocardial Biopsy with Fluoroscopic and Two-dimensional Echocardiographic Guidance: A 10-Year Experience of 228 Consecutive Procedures

Se Yong Jang, Yongkeun Cho, Joon Hyuck Song, Sang Soo Cheon, Sun Hee Park, Myung Hwan Bae, Jang Hoon Lee, Dong Heon Yang, Hun Sik Park, and Shung Chull Chae

Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea

Received: 14 April 2013 Accepted: 16 July 2013

Key Words: Endomyocardial Biopsy; Complication

INTRODUCTION

Since the introduction of catheter-based endomyocardial biopsy (EMB) by Sakakibara and Konno in 1962 (1), EMB has been a valuable tool for evaluation of cardiac tissue for cardiomyopathy, myocarditis, unexplained arrhythmia, cardiac tumor, and cardiac involvement of systemic disease. Although the complication rate is not high, this procedure is associated with potentially serious complications. It stands to reason that lowering the incidence of critical complications is a major concern in performing EMB. Fluoroscopic guidance has been used most commonly in this procedure. However, some previous studies have demonstrated the potential benefits of echocardiographic guidance (2-5). The aim of this study was to analyze the complications of transfemoral EMB with single-plane fluoroscopic and two-dimensional (2-D) echocardiographic guidance.

MATERIALS AND METHODS

Patient Selection

A total of 228 consecutive patients who underwent the EMB procedure at Kyungpook National University Hospital from January 2002 to June 2012 were enrolled in this retrospective study. All EMB procedures during this period were performed via the transfemoral approach because of the concurrent diagnostic procedures, such as coronary angiography (CAG). None of them underwent repeated biopsy procedure and all patients were in a nontransplant setting. Data on the patients were collected from medical charts, cardiac intervention reporting database, and echocardiographic and interventional images. A 12-lead ECG was performed before and after the EMB procedure. All patients underwent preprocedural 2-D echocardiography. CAG was performed in 223 patients (97.8%) in order to exclude coronary artery disease as a cause of left ventricular dysfunction and arrhythmia. The results of initial 90 patients were published previously (3).

Echocardiography

Standard 2-D transthoracic echocardiography was performed with System Five (GE Vingmed Ultrasound, Horten, Norway) and Vivid 7 (GE Vingmed Ultrasound, Horten, Norway) before EMB procedures. Left ventricular ejection fraction (LVEF) was determined from apical views using the Simpson biplane formula (6). Interventricular septum (IVS) thickness and left ventricular end-diastolic dimension (LVEDD) were determined from apical views using the Simpson biplane formula (6). Interventricular septum (IVS) thickness and left ventricular end-diastolic dimension (LVEDD) were determined from apical views using the Simpson biplane formula (6).

Endomyocardial biopsy (EMB) is one of the reliable methods for the diagnosis of various cardiac diseases. However, EMB can cause various complications. The purpose of this study is to evaluate the complication of transfemoral EMB with both fluoroscopic and two-dimensional (2-D) echocardiographic guidance. A total of 228 patients (148 men; 46.0 ± 14.6 yr-old) who underwent EMB at Kyungpook National University Hospital from January 2002 to June 2012 were included. EMB was performed via the right femoral approach with the guidance of both echocardiography and fluoroscopy. Overall, EMB-related complications occurred in 21 patients (9.2%) including one case (0.4%) with cardiac tamponade requiring emergent pericardiocentesis, four cases (1.8%) with small pericardial effusion without pericardiocentesis, two cases (0.9%) with hemodynamically unstable ventricular tachycardia (VT), one case (0.4%) with nonsustained VT, one case (0.4%) with tricuspid regurgitation, twelve cases (5.3%) with right bundle branch block. There was no occurrence of either EMB-related death or cardiac surgery. Left ventricular ejection fraction was significantly lower (32.0 ± 18.7%) vs 42.0 ± 19.1%, P = 0.023) and left ventricular end-diastolic dimension was larger (60.0 ± 10.0 mm vs 54.2 ± 10.2 mm, P = 0.013) in patients with EMB related complications than in those without. It is concluded that transfemoral EMB with fluoroscopic and 2-D echocardiographic guidance is a safe procedure with low complication rate.
tricular end-diastolic dimension (LVEDD) were measured in parasternal long axis view. One of three echocardiographic machines were used during the EMB, System Five (GE Vingmed), Vivid-Q (GE Medical Systems, Israel Ltd., Tirtar Carmel, Israel) and CX50 (Phillips Ultrasound, Andover, MA, USA).

Endomyocardial biopsy
All EMB procedures were performed by two experienced operators. A 5.5 Fr biop tome (Cordis Corp., Miami, FL, USA) with a length of 104 cm, was used and an 8 Fr Mullins transseptal sheath (Medtronic Inc., Minneapolis, MN, USA) was used for the guidance of biop tome. EMB was performed via the right femoral approach under local anesthesia. After right femoral vein was cannulated, a transseptal sheath was inserted. The sheath tip was placed toward the IVS of the right ventricle (RV) under fluoroscopic guidance and a biop tome was advanced through the sheath. To avoid capturing and damaging tricuspid valve or its subvalvular structure, the jaws of the biop tome remained closed until it touches around apical IVS. Transthoracic 2-D echocardiography was performed by assistant physicians in the opposite side of the operator in order that the operator could also check the echocardiographic images. The tip of biop tome was carefully traced by echocardiography to verify the contact with the IVS. The biop tome was then slowly withdrawn from the apical IVS to mid-IVS, then the jaws of the forcep were opened, and slightly pushed to make firm contact with the IVS. Gentle forward pressure was maintained while the jaws were closed. The specimen was obtained with gentle traction of the shaft of biop tome. Two-D transthoracic echocardiography was repeated immediately after the biopsy procedure and before discharge to check the complications.

Complications
A major complication was defined as procedure-related death or cardiac surgery, pericardial effusion requiring pericardiocentes is, sustained ventricular tachycardia (VT), persistent complete atrioventricular (AV) block, severe tricuspid regurgitation (TR), hemothorax or pneumothorax. Pericardial effusion with no further intervention/treatment, right bundle branch block (RBBB), mild to moderate TR and nonsustained VT were defined as minor complications.

Statistical analysis
Continuous variables were expressed as mean ± SD. Compari sons between continuous variables were done by use of Student t-test. Categorical variables were expressed as the number. The chi-square test was used for comparison of categorical variables. A two-tailed P < 0.05 was considered statistically signifi cant. Statistical analyses were performed using SPSS® version 20.0 for Windows® (SPSS Inc., Chicago, IL, USA).

Ethics statement
This retrospective study was approved by the institutional re view board of Kyungpook National University Hospital (No. KNUH-2013-04-047). Informed consent was waived by the board.

RESULTS
Patient characteristics
A total of 228 consecutive patients (46.0 ± 14.6 yr-old, 148 male) was analyzed. The study population consisted of 18 patients (7.9%) with assumed myocarditis, 7 patients (3.1%) with suspected infiltrative cardiac disease, 100 patients (43.9%) with unexplained left ventricular dysfunction, 100 patients (43.9%) with unexplained arrhythmia and 3 patients (1.3%) with cardiac tumor. As the study cohort included a large number of patients with cardiomyopathy, echocardiographic data showed a mean LVEF of 41.1% ± 19.3% and 115 patients (50.4%) had LVEF lower than 50% (Table 1). Among 223 patients who under went CAG, 209 patients had no significant coronary artery stenosis. In other 14 patients, CAG showed mild (< 50%) coro nary artery stenosis, which could not explain the clinical condi tion of the patients. Five patients (2.2%) did not undergo CAG in current study. In two cases of intracardiac mass, there was no need to exclude coronary artery disease. In the other three cases, we could not perform CAG due to acute renal failure or unstable condition of the patients.

During the hospitalization, four patients (1.8%) died. The causes of death were congestive heart failure due to fulminant
myocarditis in two cases. One myocarditis patient died of renal failure and another patient with lymphoma expired due to infection after chemotherapy.

**EMB procedure**
In 217 patients (95.2%), the biopsy specimens were taken only from the IVS of RV. In the other 11 patients (4.8%), in order to enhance the sensitivity, the specimens were taken from specific sites other than IVS, such as RV outflow tract, RV free wall and intracardiac mass. The number of myocardial samples taken by each procedure was 1 to 13 (mean 5.6 ± 2.3) (Table 1).

**Complications of EMB**
A total of 21 patients (9.2%) experienced complications. There was no case of multiple complications in one patient (Table 2). No case of EMB-related death or surgery was observed in this study.

**Major complication; Cardiac tamponade**
Cardiac tamponade occurred in one case (0.4%). In this patient, preprocedural echocardiography showed dilated cardiac chambers and decreased wall motion with LVEF of 24%. Ten pieces of specimen were obtained and chest discomfort developed immediately after EMB. Increasing pericardial effusion was observed on 2-D echocardiography and systolic blood pressure was decreased to 60 mmHg. Immediate pericardiocentesis was performed via a subxiphoidal approach and vital signs were stabilized. A total of 300 mL of blood was drained. No further drainage was observed after 24 hr and the catheter was removed. The pathologic diagnosis of this patient was dilated cardiomyopathy (DCMP).

**Major complication; Ventricular tachycardia**
There were two cases (0.9%) of hemodynamically unstable VT. In both cases, hemodynamically unstable VTs developed during the EMB procedure. Immediate direct current cardioversion restored sinus rhythm and patients were fully recovered without any sequelae in both cases. Final diagnoses of those patients were idiopathic VT and DCMP, respectively.

**Minor complication; Pericardial effusion**
There were four cases (1.8%) of small pericardial effusion. Two patients had impaired left ventricular systolic function, and the other two patients had normal LVEF. All patients were hemodynamically stable. One of them had mild chest discomfort after the biopsy, however the amount of pericardial effusion was stationary in follow-up echocardiography and the symptom subsided within one day. In all cases, pericardial effusion resolved within a few weeks.

**Minor complication; Nonsustained ventricular tachycardia**
One case (0.4%) of nonsustained VT was observed. VT with less than 10 ventricular complexes was developed during EMB procedure and the patient had no symptoms. The patient was pathologically diagnosed as DCMP.

**Minor complication; Tricuspid regurgitation**
New onset TR occurred in one case (0.4%). Clinical diagnosis of the patient was myocarditis. Eight pieces of specimen were obtained during the procedure. Although the patient was completely asymptomatic, follow-up 2-D echocardiography after EMB showed de novo onset of moderate TR, which showed no change during three-years follow-up.

**Minor complication; Conduction abnormality**
Any degree of AV block was not newly developed after EMB. A total of 12 patients (5.3%) experienced RBBB after the EMB procedure. No underlying left bundle branch block (LBBB) was documented before EMB in those 12 patients. Four cases were permanent and another eight cases were transient. Six patients with transient RBBB recovered within 24 hr after the EMB procedure. In another two patients with transient RBBB, RBBB resolved within one and three months after EMB, respectively.

Analysis of the incidence of complications according to the etiology of heart disease showed a trend of higher complication rate in the cardiomyopathy group (Fig. 1). Among the thirteen cases of complications developed in cardiomyopathy group, nine cases were RBBBs. It seemed that RBBBs drove such a tendency of high complication rate in cardiomyopathy group. LVEF was significantly lower and left ventricular dilatation was more severe in patients with EMB related complications than in those without. However, there were no significant differences in age, gender, IVS thickness, and number of biopsy specimen between the two groups (Table 3). There was no significant inter-operator difference in overall complication rate (7.0% vs 10.9%, P = 0.308).

**Table 2. Incidence of complications**

| Complications                                      | No. (%) of patients |
|----------------------------------------------------|---------------------|
| Overall complications                              | 21 (9.2)            |
| Major complications                                |                     |
| Procedure related death or surgery                 | 0 (0)               |
| Cardiac tamponade                                 | 1 (0.4)             |
| VT (hemodynamically unstable)                      | 2 (0.9)             |
| Severe tricuspid regurgitation                     | 0 (0)               |
| Persistent complete AV block                       | 0 (0)               |
| Hemotorax or pneumotorax                           | 0 (0)               |
| Minor complications                                |                     |
| Pericardial effusion (small amount)                | 4 (1.8)             |
| Nonsustained VT                                   | 1 (0.4)             |
| Mild to moderate tricuspid regurgitation           | 1 (0.4)             |
| Conduction abnormality                             |                     |
| Permanent RBBB                                    | 4 (1.8)             |
| Transient RBBB                                    | 8 (3.5)             |

VT, ventricular tachycardia; AV, atrioventricular; RBBB, right bundle branch block; LVEDD, left ventricular end-diastolic dimension.
DISCUSSION

EMB has an important role in the diagnosis of unexplained cardiomyopathies (7), unexplained arrhythmias (8-10), cardiac infiltrative diseases (11-13), and cardiac tumors (14,15). Furthermore, in patients with myocarditis, EMB provides not only diagnostic clues but also therapeutic and prognostic implications (16, 17). Despite all advantages of EMB-based diagnosis, EMB procedure itself is perceived to carry a high risk of major adverse events, such as cardiac tamponade and some raise a question about the role of EMB in the era of new cardiac imaging modalities such as cardiac magnetic resonance imaging (18, 19). However, histological confirmation is still needed in many patients in whom non-invasive evaluation is inconclusive. Our analysis of 228 consecutive EMB procedures with fluoroscopic and 2-D echocardiographic guidance showed very low complication rate, especially with major complications. Major complication rate of this study was 1.3% (n = 3), with one case (0.4%) of cardiac tamponade and two cases (0.9%) of sustained VT. Neither procedure related mortality nor surgery was developed. Although four cases of in-hospital death was observed in this study, no direct association was observed between the cause of their deaths and EMB.

Cardiac tamponade is one of the most concerned complications for physicians performing EMB. In the earlier surveys of fluoroscopy-guided RV EMB procedures, Yilmaz et al. reported the higher incidence of cardiac tamponade as 0.8% (n = 4 of 490) than our data (20). Deckers et al. (21) reported the similar incidence of cardiac tamponade as 0.4% (n = 2 of 546) to our data (n = 1 of 228); however, the two cases in their study were related to mortality after all. Both 2-D echocardiography and fluoroscopy were utilized as a guiding method for biopsy in our study and our data seemed to show less critical complications compared to earlier two studies. Use of 2-D echocardiography in addition to fluoroscopic guidance allows better visualization of the soft tissue structure of the heart and the tip of the biop-
ration of temporary pacemaker must be needed in the procedure of such patients. Compared to two previous studies, we could not reduce the incidence of RBBB despite the dual guidance of 2-D echocardiography and fluoroscopy. There seem two possibilities. The first one is that, as the bundle branch is invisible structure by echocardiography or fluoroscopy, damage to the bundle branch cannot be prevented. The other is that echocardiographic guidance guides the tip of forceps to some specific area of IVS around right bundle branch, resulting in higher chance of damage on right bundle branch.

In our study, cardiomyopathy group showed a trend of higher overall complication rate, in which the incidence of RBBB seemed to be a major contributor. Our data also showed that decreased LVEF and left ventricular dilatation were associated with the occurrence of complications. One possible explanation is that conduction system, with the pathologic process of cardiomyopathy, might be more easily damaged. The studies of Akar et al. and Glukhov et al. reported that there is a conduction slowing in various cardiomyopathies and the nature of it varies depending on disease etiology (28-30). The conduction system of such pathologic condition might be prone to be damaged by mechanical irritation during the biopsy procedure and that could make a higher risk of developing RBBB. Another possible explanation is that dilated chambers in cardiomyopathies can make more obtuse angle between the inferior vena cava and the longitudinal axis of the tricuspid valve and biopomte should approach the IVS with more obtuse angle. Such alteration may guide the tip of biopomte to more specific site, which can damage to right bundle branch more easily.

In conclusion, transfemoral EMB with fluoroscopic and 2-D echocardiographic guidance is a safe procedure with low complication rate. Left ventricular dysfunction and increased left ventricular dimension may be related to the occurrence of complications in EMB.

ACKNOWLEDGMENTS

We would like to thank Mr. Gun-soo Shin, Mrs. Hyun Ok Lee, Mr. Jun Rak Kim and Mr. Chang Ho Lee for their contribution to the endomyocardial biopsy procedures.

DISCLOSURE

The authors have no conflicts of interest to disclose.

REFERENCES

1. Sakakibara S, Konno S. Endomyocardial biopsy. Jpn Heart J 1962; 3: 537-43.
2. Copeland JG, Valdes-Cruz L, Sahn DJ. Endomyocardial biopsy with fluoroscopic and two-dimensional echocardiographic guidance: case report of a patient suspected of having multiple cardiac tumors. Clin Cardiol 1984; 7: 449-52.
3. Han J, Park Y, Lee H, Kang H, Kim H, Yang DH, Park HS, Cho Y, Chae SC, Jun JE, et al. Complications of 2-D echocardiography guided transfemoral right ventricular endomyocardial biopsy. J Korean Med Sci 2006; 21: 989-94.
4. Miller LW, Labovitz AJ, McBride LA, Pennington DG, Kanter K. Echocardiography-guided endomyocardial biopsy: a 5-year experience. Circulation 1988; 78: II99-102.
5. Piérard L, El Allaf D, D’Orio V, Demoulin JC, Carlier J. Two-dimensional echocardiographic guiding of endomyocardial biopsy. Chest 1984; 85: 759-62.
6. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67.
7. Ardahali H, Qasim A, Cappola T, Howard D, Hubran R, Hare JM, Baughman KL, Kasper EK. Endomyocardial biopsy plays a role in diagnosing patients with unexplained cardiomyopathy. Am Heart J 2004; 147: 919-23.
8. Kobayashi Y, Yazawa T, Baba T, Mukai H, Inoue S, Takeyama Y, Niitani H. Clinical, electrophysiological, and histopathological observations in supraventricular tachycardia. Pacing Clin Electrophysiol 1988; 11: 1154-67.
9. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Blumeke DA, Calkins H, Corrado D, Cox MG, Daubert JP, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010; 121: 1533-41.
10. Vignola PA, Aonuma K, Swayne PS, Rozanski J, Blankstein RL, Benson J, Gosselin AJ, Lister JW. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 1984; 4: 812-9.
11. Ardahali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL, Kasper EK. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005; 150: 459-63.
12. Falk RH, Skinner M. The systemic amyloidoses: an overview. Adv Intern Med 2000; 45: 107-37.
13. Kim JS, Judson MA, Donnnino R, Gold M, Cooper LT Jr, Prystowsky EN, Prystowsky S. Cardiac sarcoidosis. Am Heart J 2009; 157: 9-21.
14. Auriti A, Pandozi C, Altamura V, Cianfrocca C, Manente L, Santini M. Transthoracic echocardiography-guided biopsy of a right ventricular mass. J Cardiovasc Med (Hagerstown) 2007; 8: 274-6.
15. Unger P, Kentos A, Cogan E, Renard M, Crasset V, Stoupel E. Primary cardiac lymphoma: diagnosis by transvenous biopsy under transesophageal echocardiographic guidance. J Am Soc Echocardiogr 1998; 11: 89-91.
16. Cooper LT Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis: natural history and treatment: Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 1997; 336: 1869-81.
17. DeMello DE, Liphsis H, Jureidini S, Nouri S, Kephart GM, Gleach GJ. Cardiac localization of eosinophil-granule major basic protein in acute necrotizing myocarditis. N Engl J Med 1990; 323: 1542-5.
18. O’Donnell DH, Abbara S, Chaitiraphan V, Yared K, Killean BP, Martins R, Keane D, Cury RC, Dodd JD. Cardiac MR imaging of nonischemic cardiomyopathies: imaging protocols and spectra of appearances. Radiology 2012; 262: 403-22.

19. Yoshida A, Ishihashi-Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takehama H, Amaki M, Asakura M, Kitakaze M. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. Eur J Heart Fail 2013; 15: 166-75.

20. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukkena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 2010; 122: 900-9.

21. Deckers JW, Hare JM, Baughman KL. Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol 1992; 19: 43-7.

22. Wong RC, Abrahams Z, Hanna M, Pangrace J, Gonzalez-Stawinski G, Starling R, Taylor D. Tricuspid regurgitation after cardiac transplantation: an old problem revisited. J Heart Lung Transplant 2008; 27: 247-52.

23. Chan MC, Giannetti N, Kato T, Kornbluth M, Oyer P, Valantine HA, Robbins RC, Hunt SA. Severe tricuspid regurgitation after heart transplantation. J Heart Lung Transplant 2001; 20: 709-17.

24. Tucker PA 2nd, Jin BS, Gaos CM, Radovancevic B, Frazier OH, Wilansky S. Flail tricuspid leaflet after multiple biopsies following orthotopic heart transplantation: echocardiographic and hemodynamic correlation. J Heart Lung Transplant 1994; 13: 466-72.

25. Huddleston CB, Rosenbloom M, Goldstein JA, Pasque MK. Biopsy-induced tricuspid regurgitation after cardiac transplantation. Ann Thorac Surg 1994; 57: 832-6.

26. Platts D, Brown M, Javorsky G, West C, Kelly N, Burstow D. Comparison of fluoroscopic versus real-time three-dimensional transthoracic echocardiographic guidance of endomyocardial biopsies. Eur J Echocardiogr 2010; 11: 637-43.

27. Amitai ME, Schnittger I, Popp RL, Chow J, Brown P, Liang DH. Comparison of three-dimensional echocardiography to two-dimensional echocardiography and fluoroscopy for monitoring of endomyocardial biopsy. Am J Cardiol 2007; 99: 864-6.

28. Akar FG, Tomaselli GF. Conduction abnormalities in nonischemic dilated cardiomyopathy: basic mechanisms and arrhythmic consequences. Trends Cardiovasc Med 2005; 15: 259-64.

29. Glukhov AV, Fedorov VV, Kalish PW, Ravikumar VK, Lou Q, Janks D, Schuessler RB, Moazami N, Efimov IR. Conduction remodeling in human end-stage nonischemic left ventricular cardiomyopathy. Circulation 2012; 125: 1835-47.

30. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 2004; 95: 717-25.